Clinical trials move through four distinct phases, each with a specific purpose: Phase 1 tests safety in a small group, Phase 2 evaluates whether the treatment works, Phase 3 confirms effectiveness at large scale, and Phase 4 monitors the drug after it reaches the market. The entire process from Phase 1 through approval typically takes several years, and only a fraction of drugs that enter testing ever make it to pharmacy shelves.
Phase 1: Testing Safety and Dosage
Phase 1 is the first time a drug is given to humans. The goal isn’t to cure anyone. It’s to find out whether the treatment is safe enough to keep testing and to determine the right dose range. Researchers give increasingly larger doses to small groups, watching closely for harmful side effects, until they find the maximum tolerated dose that doesn’t cause unacceptable problems.
These trials typically enroll 20 to 80 people and last several months. Most participants are healthy volunteers, not patients with the disease the drug is meant to treat. Consent forms in Phase 1 studies often state explicitly that there is no direct benefit to the participant. The exceptions are drugs for serious illnesses like cancer or HIV, where it would be unethical to give an untested compound to someone who isn’t already sick. Researchers also study how the body absorbs, processes, and eliminates the drug during this phase.
Phase 2: Does the Treatment Actually Work?
If a drug clears Phase 1, it moves into Phase 2, where the central question shifts from “Is it safe?” to “Does it do anything useful?” These trials enroll a few dozen to a few hundred patients who actually have the condition the drug targets. Over a period of several months to two years, researchers look for signals that the treatment has a meaningful effect.
Phase 2 also refines the dosing. Researchers narrow down which dose produces the best balance of effectiveness and tolerable side effects. They gather more detailed safety data, identify which specific patient populations respond best, and figure out the best regimen (how often to take it, for how long) to carry forward into larger studies. Phase 2 essentially serves as a “go/no-go” decision point. If the results aren’t promising enough, the drug is shelved. Some trials now use a seamless Phase 2/3 design, where promising arms of a Phase 2 study roll directly into a larger confirmatory trial without starting over.
Phase 3: Large-Scale Confirmation
Phase 3 is the big test. These trials enroll hundreds to thousands of patients and run for one to four years. The treatment is compared against the current standard of care or a placebo, and participants are typically assigned randomly to one group or the other. This randomization is what allows researchers to say with confidence that any difference in outcomes is caused by the drug, not by chance or other factors.
Phase 3 results are what drug companies submit to regulatory agencies like the FDA when seeking approval to sell a treatment. The data needs to show that the drug works consistently across a large, diverse group of patients and that its benefits clearly outweigh its risks. Many drugs that looked promising in Phase 2 fail here, either because the effect shrinks when tested in a bigger population or because side effects become more apparent at scale.
Phase 4: Monitoring After Approval
Phase 4 begins after a drug has been approved and is available to the public. These trials track long-term safety and effectiveness in real-world conditions, typically involving thousands of participants. The controlled environment of earlier phases can’t catch everything: rare side effects that occur in 1 out of 10,000 people, interactions with other medications patients are taking, or problems that only emerge after years of use. Phase 4 surveillance is how those issues come to light, and it can lead to new warnings, dosage changes, or in some cases, a drug being pulled from the market entirely.
How Many Drugs Make It Through
The odds are steep at every stage. An analysis of drug development programs from 2000 to 2015 found that about 66% of drugs that enter Phase 1 advance to Phase 2. From Phase 2 to Phase 3, the success rate drops to roughly 58%. And about 59% of drugs that reach Phase 3 ultimately win approval. When you multiply those probabilities together, only about 1 in 4 drugs that begin Phase 1 testing ever reach patients. Phase 2 is often called the “valley of death” in drug development because it’s where the most promising-sounding candidates are first exposed to the harsh test of whether they actually work in sick people.
Phase 0: The Optional Precursor
Some trials include a Phase 0, which comes before Phase 1. These are exploratory studies with very limited human exposure, often lasting no more than seven days. Participants receive tiny doses of a drug (called microdoses) with no expectation of therapeutic benefit. The purpose is purely to see how the compound behaves in the human body before committing to a full Phase 1 program. Phase 0 studies are not required and are not part of the standard four-phase framework, but they can help researchers eliminate dead-end candidates early and save years of development time.
When Phases Get Compressed
The standard timeline from Phase 1 through approval can take a decade or longer. For serious or life-threatening conditions where no good treatment exists, the FDA offers expedited pathways that can shorten this process significantly. One of the most notable is accelerated approval, which has been available since 1992. Instead of waiting to prove that a drug delivers the ultimate clinical benefit (like extending survival in cancer patients), the FDA can approve it based on a surrogate endpoint: a measurable marker that is reasonably likely to predict real benefit. For example, a cancer drug might be approved because it shrinks tumors, even before long-term survival data is available.
The tradeoff is that the drug company must still run confirmatory trials after approval to verify that the surrogate endpoint translates into actual patient benefit. If those later studies don’t pan out, the FDA can withdraw the approval. Other expedited pathways include fast track designation, breakthrough therapy designation, and priority review, each of which speeds up a different part of the regulatory timeline without eliminating the requirement for evidence of safety and efficacy.